Loading...
  • Patients
  • Between 2009 and 2015, four Phase 2 trials, testing doses ranging from 2 to 25 mg of S 38093 per day have been conducted in a total of about 1,600 patients with mild to moderate Alzheimer's disease. (alzforum.org)
  • It was an international Phase 2b study evaluating 2, 5, or 20 mg per day of S 38093 co-administered with 10 mg of donepezil, given for six months, to donepezil alone in 700 patients with moderate AD. (alzforum.org)
  • The investment is part of a broader $16.5-million program being undertaken by Viron to develop novel anti-inflammatory drugs and will enable the company to develop two key compounds to treat acute coronary syndromes, rheumatoid arthritis, and organ failure in transplant patients. (marketwired.com)
  • Viron's lead compound has just entered Phase 2 clinical trials to treat patients suffering from heart disease. (marketwired.com)
  • OncoVEX GM-CSF had previously been shown to be well tolerated in a phase I clinical trial in patients with a range of tumor types, in which anti-tumor effects were seen in both injected and un-injected tumors. (bio-medicine.org)
  • As a result, many patients presenting with metastatic disease are directly enrolled into a clinical trial. (bio-medicine.org)
  • Phase I: The recommended phase 2 dose (RP2D) of galunisertib plus capecitabine in patients with chemotherapy resistant activated TGF-β signature-like CRC. (clinicaltrials.gov)
  • PMX-30063 is currently in a Phase 2 clinical trial to treat patients with Acute Bacterial Skin and Skin Structure Infections caused by Staph bacteria. (drugs.com)
  • PolyMedix's lead heptagonist compound, PMX-60056, is in a Phase 2 clinical trial in patients undergoing PCI procedures. (drugs.com)
  • HABP and VABP are serious and life-threatening hospital related pulmonary infections, especially in patients with severe underlying medical conditions," said Dr. Roy Baynes, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. (biospace.com)
  • Also, Reata has shown in numerous preclinical studies that their compounds increase the number of mitochondria, improve mitochondrial efficiency, and boost energy production by mitochondria - all would potentially be beneficial in FA patients. (curefa.org)
  • Patients must not have previously received treatment with DAB389IL-2 or DAB486IL 2 (previous candidate compound evaluated in a clinical setting). (clinicaltrials.gov)
  • TORONTO and SAN DIEGO, Nov. 18, 2016 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through clinical Phase 2 proof-of-concept, today announced positive full enrollment results from its multicenter, open label, Phase 1 study evaluating marizomib (MRZ) in combination with bevacizumab (BEV) in patients with WHO grade IV malignant glioma. (globenewswire.com)
  • These data are comparable to PFS in all patients (34% PFS 6 months, 22% PFS 9 months), suggesting a potentially unique clinical benefit of MRZ+BEV in this difficult to treat segment of glioblastomas. (globenewswire.com)
  • In an ongoing Phase 2 (MRZ monotherapy) portion of the study, a total of 15 recurrent glioma patients have been enrolled to date, receiving 0.8 mg/m 2 MRZ on days 1, 8, and 15 of a 28-day cycle. (globenewswire.com)
  • MRZ monotherapy in these patients has resulted in a partial remission in 1 patient, and stable disease in 2 additional patients, demonstrating activity of MRZ as a single agent. (globenewswire.com)
  • The IV formulation has been evaluated in more than 300 patients in multiple clinical studies in patients with solid and hematologic malignancies, either as a single agent or in combination with dexamethasone, a histone deacetylase inhibitor, or an immunomodulatory drug. (globenewswire.com)
  • The company is currently evaluating marizomib in a proof-of-concept clinical study in combination with bevacizumab (Avastin®) in patients with Grade IV malignant glioma (glioblastoma), and has received Orphan Drug designation for marizomib in glioblastoma in the United States from the FDA. (globenewswire.com)
  • SAN FRANCISCO, October 24, 2007 /PRNewswire-FirstCall/ -- Exelixis, Inc. today reported updated data from a phase 2 study of XL647, an inhibitor of EGFR, HER2 and VEGFR kinases, in previously untreated, clinically selected non-small cell lung cancer (NSCLC) patients. (drugs.com)
  • Consistent with data from the phase 2 study reported in September 2007 at the 12th International Association for the Study of Lung Cancer World Conference on Lung Cancer, 68% of the 34 patients evaluable for tumor response had clinical benefit: 10 patients had partial responses (eight confirmed, two not yet confirmed), and 13 patients had stable disease as their best response. (drugs.com)
  • The phase 2 data continue to show encouraging anti-tumor activity for XL647 given on an intermittent schedule in previously untreated clinically selected NSCLC patients. (drugs.com)
  • This open-label phase 2 trial is ongoing in previously untreated patients with stage IIIB or IV NSCLC who have adenocarcinoma histology and meet one of the following three criteria: Asian descent, female gender, or no or minimal smoking history. (drugs.com)
  • Hagop Kantarjian M.D., Professor of Medicine and Chairman of the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, said: "MDS is a very important blood disorder with significant unmet clinical needs in patients who fail approved therapies. (medicalnewstoday.com)
  • The most recent clinical data from the pivotal study in CML patients who harbor the T315I mutation were presented at ASH in December 2008. (medicalnewstoday.com)
  • Researchers found the compound TTP399 improved blood sugar control of type 2 diabetes patients in a clinical trial when it was added to metformin for six months. (upi.com)
  • Researchers found that the compound -- dubbed TTP399 for now -- improved patients' blood sugar control when it was added to the standard medication metformin for six months. (upi.com)
  • Valcarce's team put it to the test in 190 patients with type 2 diabetes. (upi.com)
  • After six months, patients on the new compound showed a greater reduction in their A1c level, versus placebo patients. (upi.com)
  • Thrombosis associated with cancer remains one of the leading complications leading to death among cancer patients, and select OT-300 compounds could represent a treatment. (bio-medicine.org)
  • tumor
  • Interleukin-2 receptor (IL-2R) expression on at least 20% of tumor cells as determined by immunohistochemistry. (clinicaltrials.gov)
  • The compound also demonstrated dose-dependent tumor growth inhibition in models of breast cancer, colorectal cancer, non-small cell lung cancer, and glioblastoma, and has been shown to cause substantial tumor regression in all models tested. (drugs.com)
  • trial
  • VXA-G1.1-NN met both the primary and secondary endpoints for safety and immunogenicity in the clinical trial. (pharmiweb.com)
  • BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncolo. (bio-medicine.org)
  • WOBURN, Mass., May 16 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage products in oncology and infectious disease, announced today that the abstract describing the interim results from its Phase II clinical trial of OncoVEX GM-CSF in advanced metastatic melanoma is now available at the American Society of Clinical Oncology (ASCO) website located at http://www.asco.org . (bio-medicine.org)
  • Senior clinical investigator, Neil N. Senzer, M.D., will present up-to-date results of the abstract entitled "Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpes virus in unresectable metastatic melanoma," at the 2008 ASCO Annual Meeting in Chicago, IL on Sunday, June 1 at 9:30am EDT during the melanoma conference session. (bio-medicine.org)
  • With GW having already opened an Investigational New Drug (IND) for Epidiolex, we are on track to commence a Phase 2/3 clinical trial in Dravet syndrome in the second half of this year. (cnbc.com)
  • Working with FARA and several FA Investigators in our Clinical Research Network, Reata has planned and launched a Phase 2/3 clinical trial of RTA 408 (MOXIe). (curefa.org)
  • The enrollment target for our registration-directed clinical trial for omacetaxine was achieved on schedule in December, and we remain on track to complete the rolling NDA submission to the FDA in mid 2009. (medicalnewstoday.com)
  • In a phase 2 clinical trial, an experimental compound -- when combined with metformin -- was more effective against diabetes than standard care, and did not cause dangerous dips in blood sugar, researchers report. (upi.com)
  • The findings, published Jan. 16 in the journal Science Translational Medicine, come from an earlier "phase 2" trial. (upi.com)
  • Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. (marketwired.com)
  • Cellceutix's anti-psoriasis drug Prurisol is presently in a bioequivalence crossover clinical trial. (marketwired.com)
  • study
  • 9) So to know the effectiveness of compounding the local anaesthetics, we have in our study, used 2% xylocaine and 0.5% bupivacaine in a 1:1 ratio. (thefreelibrary.com)
  • We believe our oral vaccine programs are significantly de-risked based on the positive clinical outcome of the BARDA-funded H1N1 influenza Phase 2 challenge study which serves as proof of concept for our technology platform as a whole," continued Latour, "and we look forward to taking our norovirus vaccine into a Phase 2 challenge study next. (pharmiweb.com)
  • Based on the favorable clinical data, a Phase 2 norovirus challenge study is expected to begin in the second half of 2018. (pharmiweb.com)
  • The MRZ+BEV combination was well tolerated with no dose limiting toxicity at 0.8 mg/m 2 , which was the highest dose of MRZ evaluated in this study. (globenewswire.com)
  • Of note, the highest amount is still lower than the lowest amount of brilacidin given in the previous phase 2 ABSSSI study, which concluded in 2012. (marketwired.com)
  • fragment
  • They then took a subset (531 compounds) of the ZoBio fragment library picked for maximal chemical and shape diversity and screened using OmpA as the reference protein. (blogspot.com)
  • type‑2 diab
  • An experimental drug may help people with type 2 diabetes curb their blood sugar without causing it to drop to dangerously low levels. (upi.com)
  • And more research is needed before TTP399 can be added to existing armaments against type 2 diabetes, said senior researcher Carmen Valcarce. (upi.com)
  • Type 2 diabetes affected over 30 million Americans in 2015, according to the American Diabetes Association. (upi.com)
  • sensor
  • Most of the damage signals originated by the sensor complexes for the G 2 checkpoint are conducted to CDC25C, the activity of which is modulated by 14-3-3. (aacrjournals.org)
  • company
  • In addition, a comprehensive appendix of all clinical stage deals since 2010 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. (researchmoz.us)
  • Exelixis
  • SOUTH SAN FRANCISCO, Calif., August 23, 2007 /PRNewswire-FirstCall/ -- Exelixis, Inc. today announced that it has agreed to a request from GlaxoSmithKline (GSK) to initiate its review of XL880 before the compound reaches proof-of-concept. (drugs.com)
  • candidates
  • This review is intended to examine the theoretical background of G 2 checkpoint abrogation as a tactic for cancer specific therapy and the status of G 2 checkpoint abrogators as clinical candidates. (aacrjournals.org)
  • Protein
  • 2-ME stabilisierte dieses p53 Protein, so daß eine ausreichende Menge funktionsfähigen p53 Proteins vorhanden war, um die Tumorzellen zu töten oder im Wachstum zu hemmen. (hu-berlin.de)
  • Another issue, Simmons said, is that some compounds disturbed the way glucokinase normally interacts with a protein that regulates it. (upi.com)
  • patient
  • 4. Duration of analgesia: This was measured as the interval between onset of analgesia and regression of analgesia by 2 segments or when the patient complained of pain, whichever occurred first. (thefreelibrary.com)
  • robust
  • The most robust correlation was seen with affinity: 94% of compounds with affinities below 0.1 µM produced structures, while only 36% of compounds with affinities above 100 µM did. (blogspot.com)
  • treatments
  • Many of the conventional anticancer treatments (including: ionizing radiation, hyperthermia, pyrimidine and purine antimetabolites, alkylating agents, DNA topoisomerase inhibitors, and platinum compounds) at least partly damage the DNA of cells. (aacrjournals.org)
  • Efforts have been made to sensitize cancer cells specifically to these treatments since the late 1960s with compounds such as caffeine ( 1 ), which at the time was thought to directly inhibit the repair machinery. (aacrjournals.org)
  • outcome
  • Because caffeine is apparently not a specific G 2 checkpoint abrogating agent (abrogator), the real outcome with regard to G 2 checkpoint abrogation was rather ambiguous ( 8 , 9 ). (aacrjournals.org)
  • responses
  • We were impressed by the broad spectrum effect of Othera's compounds in terms of their ability to inhibit not only genes involved in oxidative stress responses, but also inflammatory response genes that control angiogenesis," said Dr. Mousa. (bio-medicine.org)
  • research
  • The Project ALS Pre-Clinical Core at Columbia University is supported by generous donations from the Kleiner Family Research Initiative, Stu and Leslie Hendel, Team Chris Combs, and other donors. (projectals.org)
  • Presented at last week's 2018 Australasian Aid Conference in Canberra, the report outlined a slew of findings that provide key insight into how research can better engage aid policy…" (Cornish, 2/20). (kff.org)
  • Anticancer insights derived from cell cycle research has given birth to the idea of cell cycle G 2 checkpoint abrogation as a cancer cell specific therapy, based on the discovery that many cancer cells have a defective G 1 checkpoint resulting in a dependence on the G 2 checkpoint during cell replication. (aacrjournals.org)
  • Thus, research continued to obtain better selective G 2 checkpoint abrogators for use as clinical compounds. (aacrjournals.org)
  • nausea
  • The adverse event profile in phase 2 was consistent with phase 1: the most common adverse events were Grade 1 and 2 diarrhea, rash, fatigue, and nausea. (drugs.com)
  • currently
  • In combination with OT-551's previously known antioxidant and antiangiogenic activities, elucidation of this new mechanism provides strong support for the ophthalmic indications that Othera is currently pursuing with OT-551, as well as new non-ophthalmic indications for analogous oral compounds. (bio-medicine.org)
  • value
  • The exchange ratio in the merger agreement was determined by assigning $60 million in value to Aviragen for its financial and clinical assets and $90 million in value for Vaxart's assets. (pharmiweb.com)
  • includes
  • The report also includes numerous tables and figures that illustrate the trends and activities in clinical stage partnering and deal making since 2010. (researchmoz.us)
  • terms
  • This report contains a comprehensive listing of over 2,000 clinical stage partnering deals announced since 2010 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. (researchmoz.us)
  • News
  • Neither of the three doses, taken for a year, outperformed placebo on any measure of cognition, function, clinical global impression, or caregiver burden (see Nov 2015 conference news ). (alzforum.org)
  • target
  • To systematically target and kill civilians amounts to a war crime and the international community must act to stop it'…" (Dwyer, 2/20). (kff.org)
  • Other compounds that target glucokinase have been developed. (upi.com)
  • cancer
  • When, concurrently, oncologists began examining the mechanisms of oncogenesis in higher eukaryotes using the same molecular biology techniques as their cell cycle counterparts, it was revealed that many cancer cells have defective G 1 checkpoint mechanisms and that cancer cells depend on G 2 checkpoint far more than normal cells ( 4 , 5 ). (aacrjournals.org)
  • The original attempts using caffeine to disrupt the G 2 checkpoint to sensitize G 1 -defective cancer cells were published in 1995 ( 6 , 7 ). (aacrjournals.org)